Loading…
Loading…
BLLN (BillionToOne, Inc.) is a recent IPO.
It began trading on November 6, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisions MENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Ethan Dmitrovsky, MD, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology.
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
According to a Form 4 filing, a BillionToOne executive sold 801 shares of Class A Common Stock at $124.91 per share for a total transaction value of $100,053 on July 1, 2026. The disposition reduced the insider's direct Class A common equity holdings by 4% in this transaction.
Tom Gardner makes the case for fifty-stock portfolios and AI-powered research, then names five companies to consider owning for the next five-plus years.
Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so far this year.
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer
Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts MENLO PARK, Calif., June 29, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the publication of Longitudinal Methylated ctDNA Increases Predict Immunotherapy Progression Across Solid Tumors , a peer-reviewed study demonstrating that Northstar Response® was a stronger predictor of survival than standard-of-care imaging in patients with advanced solid tumors receiving immunotherapy or immunotherapy combination therapy, and that the addition of molecular monitoring to imaging provided greater predictive power than imaging alone.
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for BLLN and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.